News | May 26, 2009

AMG International Seeks CE Mark for Coronary Stent With Bioabsorbable Polymer

May 26, 2009 – AMG International GmbH last week submitted its second-generation drug-eluting stent (DES), Itrix, for regulatory review in Europe. The stent offers a bioabsorbable polymer that holds the drug.

After the polymer dissolves, the metallic part of the stent is left behind, reducing the potential for complications associated with vessel irritation and thrombosis caused by DES polymer coatings.

Working with the guidance of its global medical advisory board of interventional cardiologists, AMG has completed its pivotal study and is awaiting CE approval to initiate the commercialization of its latest innovation. AMG expects to launch its technology in the later part of 2009 or first half of 2010.

The Itrix platform is equipped with a sophisticated polymer that degrades after the release of the drug rapamycin, which the company said is efficient in avoiding early thrombotic and restenosis events post implantation. The drug is used to stop the body's natural reaction to the implantation of the stent and to help prevent restenosis.

The choice of drug as well as the time the polymer will stay on the stent is adjusted to maximize the absorption of the drug and to ensure the best potential results. The stent platform that is left is a proprietary technology that uses the company’s carbon-ion process to significantly enhance biocompatibility after the drug and the bioabsorbable coating have been absorbed by the body.

"This technology could represent a breakthrough in the next generation technology in the treatment of heart disease,” said Dr. Martin Rothman, a professor of interventional cardiology from the London Chest Hospital, and one of the company's medical advisers. “With early clinical results looking promising this could significantly reduce the complication rates associated with some of the current technology. More randomized clinical trials are necessary to determine the true efficacy of the device in varying patient’s population."

The company's clinical studies to date indicate no late stent thrombosis at two years post implant and other implant-associated complications are comparable to that of various market leading published studies.

For more information: www.amg-erle.de

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init